Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 16/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277210 | 0.77 | ADORA3 (0.37) | ADORA3ADORA2AADORA1MYCALDH1A1 | |
| SCHEMBL8279463 | 0.73 | RIPK1 (0.37) | ADORA3ADORA2AADORA1IDH1MYC | |
| SCHEMBL8277218 | 0.72 | ALDH1A1 (0.41) | ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL8279465 | 0.72 | CHRNB4 (0.38) | ADORA3ADORA2AADORA1 | |
| SCHEMBL8277209 | 0.71 | ADORA3 (0.37) | ADORA3ADORA2AADORA1 | |
| SCHEMBL8277247 | 0.71 | ADORA3 (0.35) | ADORA3ADORA2AADORA1 | |
| SCHEMBL13895212 | 0.69 | F2 (0.36) | IDH1ALDH1A1 | |
| SCHEMBL8277276 | 0.68 | P2RX7 (0.45) | — | |
| SCHEMBL8290137 | 0.67 | TNKS2 (0.33) | IDH1 | |
| SCHEMBL19997178 | 0.66 | GSK3B (0.40) | ADORA3ADORA2AADORA1IDH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-30 | — | — | US | disclosed |
| US-8536136-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| EP-1692157-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2468744-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2361925-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2311851-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-08 | — | — | US | disclosed |
| US-7683033-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683033-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2005077969-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031277-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | ADORA3 4052/4885ADORA2A 4095/4885ADORA1 3907/4885 |
| US-20100173851-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | ADORA3 3670/4885ADORA2A 3751/4885ADORA1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.